First Trust Advisors LP boosted its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 78.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 943,726 shares of the biopharmaceutical company’s stock after buying an additional 415,275 shares during the quarter. First Trust Advisors LP owned approximately 0.06% of Bristol-Myers Squibb worth $57,832,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also made changes to their positions in BMY. Renaissance Technologies LLC grew its position in shares of Bristol-Myers Squibb by 108.5% in the second quarter. Renaissance Technologies LLC now owns 13,488,200 shares of the biopharmaceutical company’s stock valued at $751,563,000 after purchasing an additional 7,020,200 shares during the last quarter. Franklin Resources Inc. grew its position in shares of Bristol-Myers Squibb by 185.2% in the second quarter. Franklin Resources Inc. now owns 6,098,935 shares of the biopharmaceutical company’s stock valued at $339,830,000 after purchasing an additional 3,960,191 shares during the last quarter. Jennison Associates LLC grew its position in shares of Bristol-Myers Squibb by 16.2% in the third quarter. Jennison Associates LLC now owns 26,854,242 shares of the biopharmaceutical company’s stock valued at $1,711,689,000 after purchasing an additional 3,735,453 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Bristol-Myers Squibb by 2,990.5% in the second quarter. Janus Henderson Group PLC now owns 3,634,128 shares of the biopharmaceutical company’s stock valued at $202,494,000 after purchasing an additional 3,516,536 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in shares of Bristol-Myers Squibb by 42,071.5% in the second quarter. Arrowstreet Capital Limited Partnership now owns 3,331,549 shares of the biopharmaceutical company’s stock valued at $185,634,000 after purchasing an additional 3,323,649 shares during the last quarter. 71.49% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $66.07 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The stock has a market capitalization of $108,730.02, a P/E ratio of 111.98, a P/E/G ratio of 2.05 and a beta of 0.98. Bristol-Myers Squibb Co has a 12 month low of $51.56 and a 12 month high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. During the same period in the previous year, the company posted $0.63 earnings per share. The firm’s revenue for the quarter was up 3.9% compared to the same quarter last year. research analysts predict that Bristol-Myers Squibb Co will post 3.2 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.42%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is presently 271.19%.
Several equities analysts have recently commented on BMY shares. Citigroup set a $72.00 target price on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Tuesday, December 5th. BMO Capital Markets set a $49.00 target price on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Monday, December 11th. Vetr downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 target price on the stock. in a research report on Friday, December 22nd. Zacks Investment Research downgraded Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, Credit Suisse Group set a $62.00 target price on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, January 22nd. Three analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $66.30.
ILLEGAL ACTIVITY NOTICE: This story was reported by Stock Observer and is the property of of Stock Observer. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thestockobserver.com/2018/03/20/bristol-myers-squibb-co-bmy-holdings-boosted-by-first-trust-advisors-lp.html.
Bristol-Myers Squibb Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.